ENALADEX 5 MG

国家: 以色列

语言: 英文

来源: Ministry of Health

现在购买

资料单张 资料单张 (PIL)
17-08-2016
产品特点 产品特点 (SPC)
07-08-2022
公众评估报告 公众评估报告 (PAR)
14-11-2019

有效成分:

ENALAPRIL MALEATE

可用日期:

DEXCEL LTD, ISRAEL

ATC代码:

C09AA02

药物剂型:

TABLETS

组成:

ENALAPRIL MALEATE 5 MG

给药途径:

PER OS

处方类型:

Required

厂商:

DEXCEL LTD, ISRAEL

治疗组:

ENALAPRIL

治疗领域:

ENALAPRIL

疗效迹象:

Treatment of essential hypertension, renovascular hypertension congestive heart failure and to reduce mortality in patients with all degrees of heart failure. To retard the development of symptomatic heart failure in asymptomatic patients with left ventricular dysfunction.

授权日期:

2014-11-11

产品特点

                                SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
ENALADEX 5mg
ENALADEX 10mg
ENALADEX 20mg
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ENALADEX 5mg
Each tablet contains Enalapril maleate 5 mg
Excipient with known effect:
Each tablet contains approximately 282 mg Lactose
ENALADEX 10mg
Each tablet contains Enalapril maleate 10 mg
Excipient with known effect:
Each tablet contains approximately 130 mg Lactose
ENALADEX 20mg
Each tablet contains Enalapril maleate 20 mg
Excipient with known effect:
Each tablet contains approximately 260 mg Lactose
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablet
ENALADEX 5mg are white, round, biconvex tablets, bisected on one side.
The tablet can be divided into equal doses.
ENALADEX 10mg / 20mg are pink, round, biconvex tablets, quadrisected
on
one side.
The tablet can be divided into equal doses.
4.
CLINICAL PARTICULARS
4.1. THERAPEUTIC INDICATIONS

Treatment of essential hypertension

Treatment of renovascular hypertension

Treatment of congestive heart failure and to reduce mortality in
patients
with all degrees of heart failure

To retard the development of symptomatic heart failure in asymptomatic
patients with left ventricular dysfunction
4.2. POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The absorption of Enalapril is not affected by food.
The dose should be individualized according to patient profile (see
section
4.4) and blood pressure response.
Paediatric population
There is limited clinical trial experience of the use of Enalapril in
hypertensive
paediatric patients (see sections 4.4, 5.1 and 5.2).
Hypertension
The initial dose is 5 to maximally 20 mg, depending on the degree of
hypertension and the condition of the patient (see below). Enalapril
is given
once daily. In mild hypertension, the recommended initial dose is 5 to
10 mg.
Patients with a strongly activated renin-angiotensin-aldosterone
system, (e.g.
renovascular hypertension, salt and/or volume depletion, cardiac
decompensation, or severe hypertension) m
                                
                                阅读完整的文件
                                
                            

其他语言的文件

资料单张 资料单张 阿拉伯文 07-08-2022
资料单张 资料单张 希伯来文 14-11-2019

搜索与此产品相关的警报

查看文件历史